“KAI-1678, a Novel Inhibitor of Protein Kinase C Epsilon, Attenuates Hyperalgesiaand Allodynia in Three Neuropathic Pain Models in Rodents”
Stephen D. Harrison, Ph.D., Senior Vice President, Research commented, “The findings being presented at this year’s Society for Neuroscience meeting provide additional validation for our program advancing the first isozyme-selective, epsilon PKC inhibitor in the clinic. The localization of epsilon PKC in pain receptor neurons made this a particularly interesting therapeutic target for the modulation of acute pain. Applying our expertise in PKC and in the delivery of peptides into the cell, we were able to create a promising clinical candidate against this target, which will soon progress into mid-stage trials in patients.”
An estimated 50 million people in the United States suffer from some form of persistent pain, while another 25 million suffer acute pain each year as a result of injury or surgery. According to a survey by the American Pain Society, four out of ten people suffering moderate to severe pain were unable to find adequate pain relief.
Additional information on the poster presentations at Neuroscience 2008:
Monday, Nov. 17, 2008, 4:00pm
|Session MM4, Inflammatory Pain II|
|Poster # 468.16|
“KAI-1678, a Novel Inhibitor of Protein Kinase C Epsilon, Attenuates Mechanical
Wednesday, Nov. 19, 2008, 9:00am
|Session NN21, Neuropathic Pain Modulation II|
|Poster # 774.10|
“KAI-1678, a Novel Inhibitor of Protein Kinase C Epsilon, Attenuates Hyperalgesia
KAI-1678 is an isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway. Epsilon PKC is a well-validated target for both inflammatory and neuropathic pain in the preclinical, peer-reviewed literature. KAI’s approach is the first to enable the specificity of action required to make epsilon PKC inhibition a viable clinical approach.
KAI-1678 has been shown to be highly effective at reducing pain responses in preclinical models of both neuropathic and inflammatory pain.
About KAI Pharmaceuticals
KAI is a drug discovery and development company with multiple, novel clinical-stage programs in cardiovascular disease and pain. KAI’s lead product candidate, KAI-9803, is partnered with Bristol-Myers Squibb and has demonstrated efficacy in reducing damage to heart and improving cardiac function in myocardial infarctions (MI) patients undergoing balloon angioplasty. KAI’s second clinical program, KAI-1678, is a promising, first-in-class drug candidate that may address both the inflammatory and neuropathic pain markets.
KAI’s expertise is in the selective modulation of intracellular protein:protein interactions and delivery of peptides into the cell. This approach has broad potential and has been validated clinically. The Company has applied its core expertise to discover highly potent and selective inhibitors and activators for validated protein kinase C (PKC) isozymes. KAI is based in South San Francisco, California.
KAI Pharmaceuticals, Inc.
Kristine M. Ball, 650-244-1131
Chief Financial Officer
Burns McClellan, for KAI Pharmaceuticals
Justin Jackson, 212-213-0006 ext. 327
Juliane Snowden, 212-213-0006 ext. 343